Quetiapine
Cross-source consensus on Quetiapine from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Dosage & preparation
Comparisons
Highlighted claims
- Quetiapine is the comparator because it has a robust evidence base in bipolar depression. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
- Quetiapine is one of the few NICE-recommended treatments and is widely prescribed in primary care. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
- The ASCEnD medication guide suggests a quetiapine maximum dose of 300 mg/day. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
- Quetiapine monotherapy has been described as more cost-effective than other bipolar depression treatments. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
- If quetiapine remains superior, ASCEnD findings would reinforce caution about antidepressant use in bipolar depression. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol